<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03797937</url>
  </required_header>
  <id_info>
    <org_study_id>2018BDM2</org_study_id>
    <nct_id>NCT03797937</nct_id>
  </id_info>
  <brief_title>Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II</brief_title>
  <official_title>Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National MS Center Melsbroek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National MS Center Melsbroek</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this longitudinal study is to (1) explore the association between the gut&#xD;
      microbiota and inflammatory disease activity in early onset multiple sclerosis, (2)&#xD;
      investigate whether/how gut microbial composition vary when patients experience a relapse,&#xD;
      and (3) to assess whether the gut microbiota shows increased similarities between affected&#xD;
      pairs of first-degree relatives within the same family when compared with discordant pairs of&#xD;
      first-degree relatives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using metagenomics, as well as clinical, immunological, and radiological observations, the&#xD;
      investigators will investigate if active relapsing-remitting multiple sclerosis patients have&#xD;
      a more pro-inflammatory gut microbiota signature than multiple sclerosis patients with less&#xD;
      active disease and matched healthy controls.&#xD;
&#xD;
      More specifically, the investigators will investigate whether temporal variability of the gut&#xD;
      microbiota is related to inflammatory disease activity in multiple sclerosis, whether changes&#xD;
      in the gut microbiota are predictive of future inflammatory disease activity in multiple&#xD;
      sclerosis, and whether gut microbiota characteristics are predictive of the disease course&#xD;
      after 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evidence for active disease</measure>
    <time_frame>3 years</time_frame>
    <description>Time to first relapse (after baseline) will be reported for all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological evidence for active disease</measure>
    <time_frame>3 years</time_frame>
    <description>Occurrence of new contrast-enhancing T1 hyper intense lesions, or changes in white matter lesion volume (i.e. new or enlarging T2 hyper intense lesions)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Multiple sclerosis (MS) patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy controls will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple sclerosis (MS) patients undergoing a relapse</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Multiple sclerosis (MS) patients undergoing a relapse will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple sclerosis (MS) patients from multiplex MS families</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Multiple sclerosis (MS) patients from multiplex MS families will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic resonance imaging (MRI)</intervention_name>
    <description>MRI scanner</description>
    <arm_group_label>Multiple sclerosis (MS) patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria patients:&#xD;
&#xD;
          -  Diagnosis of MS (as defined by the 2010 McDonald criteria).&#xD;
&#xD;
          -  Occurrence of symptoms no longer than 5 years before baseline.&#xD;
&#xD;
          -  Aged 18-65.&#xD;
&#xD;
          -  Willingness to participate in the study and to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria patients:&#xD;
&#xD;
          -  Treatment with high doses of systemic steroids 2 months before baseline.&#xD;
&#xD;
          -  Use of antibiotics 3 months before baseline.&#xD;
&#xD;
          -  Chronic gastrointestinal disease (e.g. inflammatory bowel disease, colon cancer).&#xD;
&#xD;
          -  Other immune-mediated or autoimmune diseases (e.g. rheumatoid arthritis, diabetes type&#xD;
             1 and 2, psoriasis).&#xD;
&#xD;
        Additional inclusion criteria for MS patients undergoing a relapse:&#xD;
&#xD;
        â€¢ Ability to provide a faecal sample within 4 weeks from onset of the first symptoms&#xD;
        suggestive of a relapse, before cortisone treatment. A relapse is defined by a new clinical&#xD;
        sign or clinical worsening of a previous sign/symptom persisting for &gt;=24 hours in the&#xD;
        absence of fever.&#xD;
&#xD;
        Additional exclusion criteria for MS patients undergoing a relapse:&#xD;
&#xD;
          -  Treatment with cortisone before collection of baseline faecal sample.&#xD;
&#xD;
          -  Evidence of a relapse less than 2 months before baseline.&#xD;
&#xD;
          -  Switching disease modifying treatment less than 2 months before baseline.&#xD;
&#xD;
        Inclusion criteria healthy controls:&#xD;
&#xD;
          -  Willingness to participate to the study and to sign the informed consent.&#xD;
&#xD;
          -  Aged &gt;=18.&#xD;
&#xD;
        Exclusion criteria healthy controls:&#xD;
&#xD;
          -  Neurodegenerative disorders.&#xD;
&#xD;
          -  Chronic gastrointestinal disease (e.g. inflammatory bowel disease, colon cancer) or&#xD;
             autoimmune diseases (e.g. rheumatoid arthritis, diabetes type 1, psoriasis).&#xD;
&#xD;
          -  Use of antibiotics 3 months before baseline.&#xD;
&#xD;
          -  Treatment with high doses of systemic steroids 2 months before baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie D'hooghe, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National MS Center Melsbroek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Van Remoortel</last_name>
    <phone>32-2-5978724</phone>
    <email>ann.vanremoortel@mscenter.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick Van Merhaegen</last_name>
      <phone>024763435</phone>
      <email>annick.vanmerhaegenwieleman@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationaal Multiple Sclerose Centrum Melsbroek</name>
      <address>
        <city>Melsbroek</city>
        <state>Vlaams-Brabant</state>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Van Remoortel</last_name>
      <phone>025978724</phone>
      <email>ann.vanremoortel@mscenter.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2019</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National MS Center Melsbroek</investigator_affiliation>
    <investigator_full_name>Marie D'hooghe</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

